Peptide vaccination of advanced melanoma patients elicits CD8+ T cell responses that are restrained by PD‐1 and TIM‐3, and blockade of these receptors during ex vivo restimulation enhances their proliferative capacity and effector cytokine production.343. Here, CD8A is linked to melanoma.